Table 1.
Demographic and Clinical Characteristic of Individuals With SARS-CoV-2 Infection
| Total Patients | 462 |
|---|---|
| Age (median [range]) in years | 11 [0–24] |
| Sex (%) | |
| Female | 208 (45.02) |
| Male | 254 (54.98) |
| Race (%) | |
| Black | 244 (52.81) |
| White | 187 (40.48) |
| Multiracial | 20 (4.33) |
| Asian | 5 (1.08) |
| Unknown | 1 (0.22) |
| Other | 5 (1.08) |
| Ethnicity (%) | |
| Non-Hispanic/non-Latino | 400 (86.58) |
| Hispanic/Latino | 50 (10.82) |
| Not specified | 12 (2.60) |
| Diagnosis (%) | |
| HIV | 26 (5.63) |
| Leukemia/Lymphoma | 87 (18.83) |
| SCD | 140 (30.30) |
| ST/NO | 145 (31.39) |
| Othera | 64 (13.85) |
| Cancer diagnosis (%) | |
| Yes | 245 (53.03) |
| No | 217 (46.97) |
| Received chemotherapy (%) | |
| Yes | 100 (40.82) |
| No | 145 (59.18) |
| SARS-COV-2 vaccination prior to infection (%) | |
| No | 369 (79.87) |
| Yes | 93 (20.13) |
| Number of vaccine doses (median [IQR]) | 2.00 [1.00, 2.00] |
| Pfizer-BioNTech (%) | |
| Yes | 67 (72.04) |
| Moderna (%) | |
| Yes | 10 (10.75) |
| Janssen (%) | |
| Yes | 18 (19.35) |
| Reason for testing (%) | |
| Symptoms | 172 (37.23) |
| Asymptomatic screening | 290 (62.77) |
| Did the patient become symptomatic? (%) | |
| No | 205 (70.69) |
| Yes | 85 (29.31) |
| Was episode initial or a reinfection (%) | |
| Initial infection | 454 (98.27) |
| Reinfection | 8 (1.73) |
| Days from previous infectious episode (median [IQR]) | 91.00 [74.25, 142.50] |
| SARS-CoV2- Variant (%) | |
| Omicron | 202 (43.72) |
| Ancestral | 103 (22.29) |
| Delta | 61 (13.20) |
| Alpha | 10 (2.16) |
| Epsilon | 1 (0.22) |
| Undetermined | 85 (18.40) |
| Symptoms within 28 days of Day 0? (%) | |
| Yes | 247 (53.46) |
| No | 215 (46.54) |
| Fever (%) | |
| Yes | 155 (62.75) |
| No | 92 (37.25) |
| Headache (%) | |
| Yes | 47 (19.03) |
| No | 200 (80.97) |
| Cough (%) | |
| Yes | 157 (63.56) |
| No | 90 (36.44) |
| Sore throat (%) | |
| Yes | 42 (17.00) |
| No | 205 (83.00) |
| Loss of smell or taste (%) | |
| Yes | 26 (10.53) |
| No | 221 (89.47) |
| Shortness of breath (%) | |
| Yes | 22 (8.91) |
| No | 225 (91.09) |
| Diarrhea (%) | |
| Yes | 20 (8.10) |
| No | 227 (91.90) |
| Hospitalization (%) | |
| Yes | 51 (11.04) |
| Already hospitalized for reasons other than COVID-19 | 26 (5.63) |
| No | 385 (83.33) |
| ICU (%) | |
| Yes | 8 (1.73) |
| No | 69 (14.94) |
| Not hospitalized | 385 (83.33) |
| Any respiratory symptoms at Day 0? (%) | |
| No | 281 (61.22) |
| Yes | 178 (38.78) |
| Respiratory symptoms at Day 0 (%) | |
| LRTI | 17 (9.55) |
| URTI | 161 (90.45) |
| Progression to LRTI (%) | |
| No | 440 (99.55) |
| Unknown | 1 (0.23) |
| Yes | 1 (0.23) |
| Death (%) | |
| Yes | 2 (0.43) |
| No | 460 (99.57) |
| MIS-C (%) | |
| Yes | 1 (0.26) |
| No | 380 (99.74) |
| Received steroids within 28 days (%) | |
| Yes | 12 (2.65) |
| No | 440 (97.35) |
| Received convalescent plasma within 28 days (%) | |
| Yes | 2 (0.43) |
| No | 460 (99.57) |
| Received remdesivir within 28 days (%) | |
| Yes | 24 (5.19) |
| No | 438 (94.81) |
| Remdesivir usage (%) | |
| Prevent progression | 15 (62.50) |
| Treatment of severe COVID-19 | 9 (37.50) |
| Duration of remdesivir use (median [IQR]) | 3.00 [3.00, 5.00] |
aFor a complete list of conditions included in Other please refer to Supplementary Table 16.